Cargando…
BAP1 promotes osteoclast function by metabolic reprogramming
Treatment of osteoporosis commonly diminishes osteoclast number which suppresses bone formation thus compromising fracture prevention. Bone formation is not suppressed, however, when bone degradation is reduced by retarding osteoclast functional resorptive capacity, rather than differentiation. We f...
Autores principales: | Rohatgi, Nidhi, Zou, Wei, Li, Yongjia, Cho, Kevin, Collins, Patrick L., Tycksen, Eric, Pandey, Gaurav, DeSelm, Carl J., Patti, Gary J., Dey, Anwesha, Teitelbaum, Steven L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516877/ https://www.ncbi.nlm.nih.gov/pubmed/37740028 http://dx.doi.org/10.1038/s41467-023-41629-4 |
Ejemplares similares
-
ThPOK Inhibits Osteoclast Formation Via NFATc1 Transcription and Function
por: Zou, Wei, et al.
Publicado: (2022) -
To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001) -
Chimeric Antigen Receptor Macrophages Target and Resorb Amyloid Plaques in a Mouse Model of Alzheimer’s Disease
por: Pan, Qiuyun, et al.
Publicado: (2023) -
Osteoclasts; culprits in inflammatory osteolysis
por: Teitelbaum, Steven L
Publicado: (2006) -
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach
por: Sridaran, Dhivya, et al.
Publicado: (2023)